Nuvation Bio(NUVB.US)

Last Updated 19:00:00 ET
longbridge loading

How Does Nuvation Bio’s (NUVB) IBTROZI Update Reframe Its Long-Term Oncology Investment Narrative?

Simplywall·
US
NUVB
+6.25%
US
TMO
-0.15%
US
BIB
+4.14%
Simplywall·
US
NUVB
+6.25%
US
TMO
-0.15%
US
BIB
+4.14%

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer | NUVB Stock News

StockTitan·
US
TMO
-0.15%
US
NUVB
+6.25%
US
IXJ
+0.10%
StockTitan·
US
TMO
-0.15%
US
NUVB
+6.25%
US
IXJ
+0.10%

Nuvation Bio to Participate in Upcoming Investor Conferences

Unusual Whales·
US
NUVB
+6.25%
US
BIB
+4.14%
US
PBE
+1.36%
Unusual Whales·
US
NUVB
+6.25%
US
BIB
+4.14%
US
PBE
+1.36%

Nuvation Bio shares are trading higher after the company reported in-line Q1 EPS results and better-than-expected sales results.

benzinga_article·
US
NUVB
+6.25%
US
XLV
-0.31%
US
FBT
+1.61%
benzinga_article·
US
NUVB
+6.25%
US
XLV
-0.31%
US
FBT
+1.61%

Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)

Tip Ranks·
US
NUVB
+6.25%
US
PBE
+1.36%
US
SBIO
+3.97%
Tip Ranks·
US
NUVB
+6.25%
US
PBE
+1.36%
US
SBIO
+3.97%
© 2026 Longbridge｜Disclaimer